Oxford Biomedica signs licence, supply deal with Cabaletta Bio

Oxford Biomedica

425.50p

09:24 23/12/24

-0.23%

-1.00p

Gene and cell therapy group Oxford Biomedica on Wednesday said it had signed a new license and supply agreement on its LentiVector platform with US-based Cabaletta Bio.

FTSE 250

20,399.18

09:50 23/12/24

n/a

FTSE 350

4,467.58

09:50 23/12/24

n/a

FTSE All-Share

4,425.18

09:50 23/12/24

n/a

Pharmaceuticals & Biotechnology

19,967.03

09:49 23/12/24

1.04%

205.91

The deal gives Cabaletta a non-exclusive licence for LentiVector to be used on Chimeric autoantibody receptor T programme, DSG3-CAART, for autoimmune disease.

No financial details were revealed, but Oxford Biomendica said the arrangements of the LSA were "in line with comparable deals the group has previously secured”.